Pathophysiology of heart failure;Fisiopatologia da insuficiência cardíaca

Revista Portuguesa de Cardiologia

Volumn 23, Issue SUPPL. 2, 2004, Pages

  Cerqueira Gomes, Mário ^a,b   Ferreira, António ^a   Bettencourt, Paulo ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b NONE   (Portugal)

Author keywords

Cytokines; Dopaminergic system; Neurohormones; Ventricular remodeling

Indexed keywords

ADRENOMEDULLIN; ALDOSTERONE; BRADYKININ RECEPTOR; BRAIN NATRIURETIC PEPTIDE; ENDOTHELIN; NEUROHORMONE; NITRIC OXIDE; PROSTAGLANDIN;

ADRENERGIC SYSTEM; CHOLINERGIC SYSTEM; CYTOKINE PRODUCTION; DISEASE COURSE; DOPAMINERGIC SYSTEM; HEART FAILURE; HEART HEMODYNAMICS; HEART STROKE VOLUME; HEART VENTRICLE REMODELING; INOTROPISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM RETENTION; VASOCONSTRICTION; WATER RETENTION;

ADAPTATION, PHYSIOLOGICAL; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; INFLAMMATION MEDIATORS; NATRIURETIC PEPTIDES; NEUROTRANSMITTER AGENTS; NITRIC OXIDE; RENIN-ANGIOTENSIN SYSTEM; VENTRICULAR REMODELING;

EID: 3142684500     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Katz AM. Heart Failure: Pathophysiology, Molecular Biology and Clinical Management: Lippincott Williams & William, Philadelphia 2000.
2. Cerqueira-Gomes M, Polónia J, Brandão F, Ramalhão C, Bravo de Faria D. Mecanismos neuro-humorais na insuficiência cardíaca - da fisiopatologia a tratamento. Rev Port de Cardiol 1989;8:129-48.
3. Cerqueira-Gomes M. Heart Failure - 1993. In 3rd Autumn Symposium on Coronary Heart Disease, Lisboa. October 1993.
4. Cerqueira-Gomes M. Insuficiência Cardíaca - 1997. In Congresso Português de Cardiologia, Porto, Abril 1997.
5. Brandão F, Cerqueira-Gomes. Insuficiência Cardíaca - Um conceito em plena evolução. Rev Port. Cardiol 1996;15: 711-4.
6. Cerqueira-Gomes M. Pathogenesis of heart failure - 2000. Rev Port Cardiol 2000; 10:523-9.
7. Hassan F, Weinberg EO, Delyani J, et al. Aldosterone and cardiac hypertrophy: effects of eplerenone on LV function and hypertrophic remodeling in LV pressure overload. Circulation 1999;100:I-565.
8. Miller WL, Burnett Jr. JC. Circulating paracrine and tocrine mechanisms in heart failure. Curr Op Cardiol 1993;8: 376-82.
9. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A, for the V-HeFT VA Cooperative Group (1993). Plasma norepinephrine, plasma rennin activity and Congestive heart failure: relations to survival and the effects of the therapy in V- Heft II. Circulation 87;VI40-VI-48.
10. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, Dibianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL (1991). Effect of oral milrinone on mortality in severe heart failure. N heart failure Engl J Med 1991;325:1468-7.
11. Yusef S, Teo K (1990). Inotropic agents increase mortality in patients with congestive heart failure. (Abstract). Circulation 1990;82:III-673.
12. Dzau VJ. Autocrine and paracrine mechanisms in the pathophysiology of heart failure. Am J Cardiol 1990;70:4C-11C.
13. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH. Increased rat cardiac angiostensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypotrophy. Effects on coronary resistance, contractility, and relaxation. J. Clin Invest 1990;86:1913-20.
14. Francis GS (1990). Neuroendocrine activity in congestive heart failure. Am J Cardiol 1990;66:33D-39D.
15. Weber KT, Brilla CG, Janicki Js. Myocardial fibrosis - functional significance and regulatory factors. Cardiovasc. Res 1993;27:341-8.
16. Pitt B, Zannad F, Remme W, et al. The effect of spironolactone on morbility and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
17. Goldsmith SR. Vasopressin: a therapeutic target in congestive heart failure? Journal of Cardiac Failure 1999;5:347.
18. Suzuki T, Hoshi H, Mitsui Y (1989). Endothelin stimulates hypertrophy and contractility of neonatal rat cardiac myocytes in a serum-free medium. FEBS Lett 1989;26:149-51.
19. Brooks PD. Role of endothelin in renal fuction and dysfunction. Clin Exp Pharmacol Physiol 1996;23:3445-8.
20. Cozza EN, Gomez-Sanchez CE, Foecking MF, Chiou S. Endothelin binding to cultured calf adrenal zona glomerulosa cells and stimulation of aldosterone secretion. J Clin Invst 1989;84:1032-5.
21. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation 1992;85:510.
22. Mulder P, Buojedaini H, Richard V, Derumeaux G, Henry JP, Renet S, Opgenorth T, Thuillez C. Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure. Circulation 2000; 102:491-3.
23. Sütsch, G, Kiowski W, Yan X, Hunziker P, Christen S, Strobel W, Kim J, Rickenbacher P, Bertel O. Short term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998;98:2262-8.
24. Enable trial results show no benefit from bosetan in severe chronic heart failure - Heartwire News - Fev 7, 2002.
25. Cody RJ, Atlas SA, Laragh JH, Kubo SH, Covit AB, Ryman KS, Shaknovich A, Pondolfino K, Clark M, Camargo MJE, Scarborough RM, Lewichi JA. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal hormonal and hemodynamic responses to peptide infusion. J Clin Invest 1986;78:1362-74.
26. Calderone A, Takahashi N, Thaik CM, Colucci WS. Atrial natriuretic factor and cyclic guanosine monophosphate modulate cardiac myocyte growth and phenotype. Circulation 1994;90(Suppl I):I-317.
27. Itoh H, Pratt RE, Dzau VJ. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth cell. J Clin Invest 1990;86:1670.
28. Redfield MM, Aarhus LL, Wright RS, Burnett JC Jr. Cardiorenal and neurohumoral function in a canine model of early left ventricular dysfunction. Circulation 1993;87:2016-22.
29. Bettencourt P, Ferreira A, Sousa T, Ribeiro L, Brandão F, Polónia J, Cerqueira-Gomes M, Martins L. Brain natriuretic peptide as a marker of cardiac remodeling in hypertensive patients. International Journal of Cardiology 1999;69: 169-77.
30. Bettencourt P, Ferreira A, Dias P, Castro A, Martins L, Cerqueira-Gomes M. Evaluation of brain natriuretic peptide in the diagnosis of heart failure. Cardiology 2000;93:19-25.
31. Bettencourt P, Ferreira A, Pardal-Oliveira N, Pereira M, Queirós MC, Araújo V, Cerqueira-Gomes M, Maciel MJ. Clinical significance of brain natriuretic peptide in postmyocardial infraction patients. Clinical Cardiology 2000;23:921-7.
32. Bettencourt P, Ferreira A, Dias P, Pimenta J, Friões F, Martins L, Cerqueira-Gomes M. Predictors of prognosis in stable patients with mild to moderate heart Failure. Journal of Cardiac Failure 2000;6:306-13
33. Bettencourt P. BNP in the diagnosis and treatment of heart failure. Cardiovascular Drug Reviews.
34. Prendergast BD, Sagach VF, Shah AM. Basal release of nitric oxide augments the Frank-Starling response in the isolated heart. Circulation 1997;96:1320-9.
35. Hare JM, Givertz MM, Creager MA, Colucci WS. Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure. Potentiation of β-adrenergic inotropic responsiveness. Circulation 1998;97:161-6.
36. Kubo SH, Rector TS, Bank AJ, Tschumperlin LK, Raii L, Brunsvold N, Kraemer MD. Lack of contribution of nitric oxide to basal vasomotor tone in heart failure. Am J Cardiol 1994;74:1133-6.
37. Balligand J-L, Kelly RA, Marsden PA, Smith TW, Michel T. Control of cardiac muscle cell function by an endogenous nitric oxide signalling system. Pro Natl Acad Sci USA 1993;90:347-51.
38. Haynes WG, Hand MF, Dockrell ME, Lee MR, Hussein A, Bengamin N, Webb DJ. Physiological role of nitric oxide in regulation of renal function in humans. Am J Physiol 1997;273:F364-F371.
39. Garg UC, Hassid A. Nitric oxide generating vasodilators and 8-bromo-cyclic guanosine monophosphate in hibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-7.
40. Balligand J-L, Ungureanu-Longrois D, Simmons WW, Pimental D, Malinski TA, Kapturczak M, Taha Z, Lowenstein CJ, Davidoff AJ, Kelly RA, Smith TW, Michel T. Cytokine-inducible nitric oxide synthase expression in cardiac myocytes. J Biol Chem 1994;269:27580-8.
41. Schultz R, Panas DL, Catena R, Moncada S, Olley PM, Lopaschuk GD. The role of nitric oxide in cardiac depression induced by interleukin-1 and tumor necrosis factor-. Br J Pharmacol 1995;114:27-34
42. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
43. Stein B, Frank P, Schmitz W, Scholz H, Thoenes M. Endotoxin and cytokines induce direct cardiodepressive effects in mammalian cardiomyocytes via induction of nitric oxide synthase. J Mol Cell Cardiol 1996;28:1631-9.
44. Paulus WJ, Frantz S, Kelly RA. Nitric oxide and cardiac contractility in human heart failure: time for reappraisal. Circulation 2001;104:2318-23.
45. Fleming I, Hecker R, Busse R. Intracellular alkalinization induced by bradykinin sustains activation of the constitutive nitric oxide synthase in endothelial cell. Circ Res 1994;74:1222-6.
46. Dzau VJ, Packer M, Lilly LS, et al. Protaglandins in severe congestive heart failure. Relation to activation of the rennin-angiotensin system and hyponatremia. N Engl J Med 1984;310:347-52.
47. Wu KK. Cyclooxygenase-2 induction in congestive heart failure. Friend or foe? Circulation 1998;98:95-96.
48. Dzau VJ, Swartz SL. Dissociation of the prostaglandin and RAS during captopril therapy for chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1987;60:1101-5.
49. Krishna GG, Danovitch GM, Beck FW, Sowers JR. Dopaminergic mediation of the natriuretic response to volume expansion. J Lab Clin Med 1985;105:214-8.
50. Ferreira A, Bettencourt P, Pestana M, Correia F, Serrão P, Martins L, Cerqueira-Gomes M, Soares-da-Silva P. Heart Failure, aging, and renal synthesis of dopamine. Am J Kidney Dis 2001;38:502-509.
51. Lee MR. Dopamine and the Kidney: ten year on. Clin Sci 1993;84:357-375.
52. Ferreira A, Bettencourt P, Pestana M, Oliveira N, Serrão P, Maciel MJ, Cerqueira-Gomes M, Soares-da-Silva P. Renal synthesis of dopamine in asymptomatic post-infraction left ventricular dysfunction. Clin Sci 2000;99:195-200.
53. Ferreira A, Bettencourt P, Pimenta J, Friões F, Pestana M, Soares-da-Silva P, Cerqueira-Gomes M. The renal dopaminergic system, neurohumoral activation and sodium handling in heart failure. Am Heart J, no prelo.
54. Ferreira A, Bettencourt P, Dias P, Pestana M, Serrão P, Soares-da-Silva P, Cerqueira-Gomes M. Neurohormonal activation, the renal dopaminergic system and sodium handling in patients with severe heart failure under vasodilator therapy. Clin Sci 2001;100:557-66.
55. Kitamura K, Kanagawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993;192:553-560.
56. Jougasaki M, Wei C-M, McKinley LJ, Burnett JC Jr. Elevation of circulating and ventricular adrenomedullin I human congestive heart failure. Circulation 1995b;92:286-9.
57. Jougasaki M, Wei C-M, Aarhus LL, Heublein DM, Dandberg SM, Burnett JC Jr. Renal localization and actions of adrenomedullin: a natriuretic peptide. Am J Physiol 1995b;268:F6576-F663.
58. Szokosi I, Kinnune P, Tavi P, Weckström M, T A2th, Ruskoaho H. Evidence for camp-independent mechanisms mediating the effects of adrenomedullin, a new inotropic peptide. Circulation 1998;97:1062-70.
59. Eckberg DL, Drabinsky M, Braunwald E. Defective cardiac parasympathetic control in paitents with heart disease. N. Engl J Med 1971;258:877-83.
60. Binkler PF, Nunziata E, Nelson SD, Cody RJ. Parasympathetic withdrawal is as integral component of autonomic imbalance in congestive heart failure: demonstration in human subjects and verification in a paced canine model of ventricular failure. J Am Coll Cardiol 1991;18:464-72.
61. Nolan J, Flapan AD, Capewell S, McDonald TM, Neilson DJ. Decreased cardiac parasympathetic activity in chronic heart failure and its relation to left ventricular function. Br Heart J 1992;67:482-5.
62. Vatner DE, Sato N, Galper GB, Vatner SF. Physiological and biochemical evidence for coordinate increases in muscarinic receptors and Gi during pacing-induced heart failure. Circulation 1996;96:102-107.
63. Le Guludec D, Cohen-Solal A, Delforge J, Delahaye N, Syrota A, Merlet P. Increased myocardial muscarinic receptor density in idiopathic dilated cardiomyopathy. An in vivo PET study. Circulation 1997;96:3416-22.
64. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Eng J Med 1990;323:236-41.
65. Simonini A, Long CS, Dudley GA, Yue P, McElhinny J. Heart failure causes changes in skeletal muscle morphology and gene expression that are not explained by reduced activity. Circ Res 1996;79:128-136
66. Seta Y, Shan K, Bozkurt O, Oral H, Mann DL. Basic mechanisms in heart failure: the cytokine hypothesis. J Cardiac Failure 1996;2:243-9.
67. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Pro-inflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-6.
68. Oral H, Kapadia S, Nakano M, Torre-Amione G, Lee J, Lee-Jackson D, Young JB, Mann DL. Tumor necrosis factor-alpha and the failing human heart. Clin Cardiol 1995; 18(Suppl 4):IV20-7.
69. Bozkurt B, Kribbs SB, Clubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodelling in rats. Circulation 1998;97: 1382-91.
70. Deswal A, Bozkurt B, Seta Y, et al. Safety and efficacy of a soluble P75 tumor necrosis factor (enbrel, etanercept) in patients with advanced heart failure. Criculation 1999; 99:3224-6.
71. Keith M, Geranmavegan A, Sole MJ, et al. Increased oxidative stress in paitents with congestive heart failure. J Am Coll Cardiol 1998;31:1352-6.
72. Mallat Z, Philip I, Lebret M, et al. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: A potential role for in vivo oxidant stress in ventricular dlilatation and progression to heart failure. Circulation 1998;97:1536-9.
73. Hayashida W, Kumada T, Nohara R, et al. Left ventricular regional wall stress in dilated cardiomyopathy. Circulation 1990;82:2075.
74. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 1996;28:506-14.
75. Givertz MM, Colucci WS. New targets for heart-failure therapy: Endothelin, inflammatory cytokines, and oxidative stress. Lancet 1998;352(Suppl 1):SI134-8.
76. Cohn JN, Ferrari R, Sharpe N. Cardiac remodelling - Concepts and clinical implications: A consensus paper from an international forum on cardiac remodelling. J Am Coll Cardiol 2000;35:569.
77. Mann DL. Mechanisms and models in heart failure. A combinatorial approach. Circulation 1999;100:999-1008.
78. Eichhorn EJ, Bristow M. Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 1997;94:2285-96.
79. Tsutsui H, Spinale FG, Nagatsu M, et al. Effects of chronic β-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. J Clin Invest 1994;93:2639-48.
80. Josue O. Hypertrophie cardioque caus'ee par l'adrenaline et la toxine typhique. C R Soc Biol (Paris). 1907;63: 285-90.
81. Simon M, Downing SE. Coronary vasoconstriction and catecholamine cardiomyopathy. Am Heart J 1985;109-297.
82. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, Schimdt U, Semigran MJ, Dee GW, Khaw B-A. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996;335:1182-9.
83. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JÁ, Quaini E, Di Loreto C, Beltrami CA, Krajewsky S, Reed JC, Anversa P. Apoptosis in the failing human heart. N Engl J Med 1997;336:1131-41
84. Bing OHL. Hypothasis: Apoptosis may be a mechanism for the transition to the heart failure with chronic pressure overload. J Moll Cell Cardiol 1994;26:943-8.
85. Cheng W, Li B, Kajstura J, Li P, Wolin MS, Sonnenblick EH, Hintze TH, Olivetti G, Anversa P. Stretch-induced programmed myocytes cell death. J Clin Invest 1995;96:2247-59.
86. Leri A, Claudio PP, Li Q, Wang X, Reiss K, Wang S, Malhotra A, Kajstura J, Anversa P. Stretch-mediated release of angiotensin II induces myocytes apoptosis by activating p53 that enhances the local rennin-angiotensin system and decreases the Bc-2-to Bax protein ratio in the cell. J Clin Invest 1998;101:1326-42.
87. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL, Glembotski CC, Quintana PJE, Sabbadini RA. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes: involvement of the sphingolipid signalling cascade in cardiac cell death. J Clin Invest 1996;98:2854-65.
88. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley JA III, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage heart failure. Circulation 1998;97: 1708-15.
89. Tyagi SC, Kumar S, Voelker DJ, Reddy HK, Janicki JS, Curtis JJ. Differential gene expression of extracellular matrix components in dilated cardiomyopathy. J Cell Biochem 1996;63:63:185-98.
90. Li YY, Feldman AM, Sun Y, McTiernan CF. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998;98:1728-34.
91. Weber KT. Extracellular matrix remodelling in heart failure. A role for de novo angiotensin II generation. Circulation 1997;96:4065-82.
92. Weber KT, Sun Y, Ǵuarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994;23:869-77.
93. Linzbach Aj. Heart failure from the point of view of quantitative anatomy. Am J Cardiol 1960;69:70-382.
94. Ross J Jr. Afterload mismatch in aortic and mitral valve disease: implications for surgical therapy. J Am Coll Cardiol 1985;5:811-26.
95. Ross JJ. Mechanisms of cardiac contraction. What roles for preload, afterload and inotropic state in heart failure? Eur Heart J 1984;4(Suppl A):19-28.
96. Pouleur H, Rouseau MF, van Eyll C, Melin J, Youngblood M, Yusuf S. Cardiac mechanisms during development of heart failure: SOLVD Investigators. Circulation 1993; 87:IV14-IV20.
97. Vatner SF. Reduced subendocardial myocardial perfusion as one mechanism for congestive heart failure. Am J Cardiol 1988;62:94E-98E.
98. LeGrice IJ, Takayama Y, Holmes JW, Covell JW. Impaired subendocardial function in tachycardia-induced cardiac failure. Am J Physiol 1995;268:H788-H1794.
99. Kapadia S, Oral H, Lee J, Nakano M, Taffet Ge, Mann DL. Hemodynamic regulation of tumor necrosis factor-gene and protein expression in adult feline myocardium. Circ Res 1997;81:187-95.
100. Sadoshima JL, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993;75:977-84.
101. Kono T, Sabbah HN, Rosman H, Alam M, jafri S, Goldstein S. Letf ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. J Am Coll Cardiol 1992;20:1594-8.
102. Greenberg B, Quinones MA, Koipillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfuction. Circulation 1995;91:2573-81.
103. Sharpe N. Cardiac remodelling in congestive heart failure. In Jeffrey D. Hosenput and Barry H. Greenberg (eds) Congestive Heart Failure, 2nd edition, pp101-116,Lippincott Williams & Wilkins, Philadelphia 2000.
104. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodelling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1998;29:1060-6.
105. McCarthy PM, Nakatani S Vargo R, et al. Structural and left ventricular histologic changes after implantable LVAD insertion. Ann Thorac Surg 1995;59:609-13.